The frequency of RASi ever-users in the NAFLD development case and control cohorts were 10.1% (n = 238/2351) and 10.0% (n = 234/2351), respectively (Table 2). This evidence concerns the gene MMP19 and metabolic dysfunction-associated steatotic liver disease.